Bunazosin
From Infogalactic: the planetary knowledge core
File:Bunazosin.png | |
Systematic (IUPAC) name | |
---|---|
1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one
|
|
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
CAS Number | 80755-51-7 |
ATC code | none |
PubChem | CID: 2472 |
ChemSpider | 2378 |
UNII | 9UUW4V7G2H |
ChEMBL | CHEMBL188185 |
Chemical data | |
Formula | C19H27N5O3 |
Molecular mass | 373.44 g/mol |
|
|
|
|
(verify) |
Bunazosin (INN) is an alpha 1 antagonist. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Alpha blockers
- Phenol ethers
- Quinazolines
- Amides
- Diazepanes
- Antihypertensive agent stubs